Matthew J. Kuhn1, Howard A. Rowley2,
Michael V. Knopp3, Kenneth R. Maravilla4, Zoran
Rumboldt5
1Radiology, University of Illinois at
Peoria, Peoria, IL, United States; 2Radiology, University of
Wisconsin, Madison, WI, United States; 3Radiology, Ohio State
University, Columbus, OH, United States; 4Radiology and Surgery,
University of Washington, Seattle, WA, United States; 5Radiology,
Medical University of South Carolina, Charleston, SC, United States
382
patients were randomized to receive 2 MR exams within 2 days to 2 weeks with
equal 0.1mmo/kg doses of either gadobenate dimeglumine (N=382) or a
comparator gadolinium agent. Blinded experts assessed post-contrast images
for both qualitative (eg, global contrast enhancement, lesion-to-brain
contrast, lesion delineation, internal lesion morphology and structure, tumor
vascularization, and global image preference) and quantitative (eg,
contrast-to-noise ratio [CNR]; percent lesion enhancement) efficacy
parameters. In all six studies, images produced following administration of
Gd-BOPTA demonstrated greater contrast enhancement, provided more diagnostic
information including additional lesion detection, and were significantly
preferred by experienced, blinded neuroradiologists.